Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Hyeong Seok Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4711-3603; OpenAlex author ID A5077405154, A5132912915. Sources: OpenAlex.

Their work

Papers
13 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: 6 papers · 2026: 1 paper

Papers 13

  1. Multivisceral resection for pancreatic ductal adenocarcinoma with adjacent organ invasion: a propensity score-matched analysis. Co-author DOI 10.1016/j.gassur.2026.102412↗
  2. Synthetic data generation method improves risk prediction model for early tumor recurrence after surgery in patients with pancreatic cancer. Co-author DOI 10.1038/s41598-025-15800-4↗
  3. Implications of portal vein/superior mesenteric vein involvement in pancreatic cancer: A comprehensive correlation from preoperative radiological assessment to… Co-author DOI 10.1097/js9.0000000000002307↗
  4. The impact of distress at diagnosis in patients with pancreatic cancer undergoing pancreatectomy. Co-author DOI 10.1186/s12885-025-14365-9↗
  5. Prognostic Accuracy of ypTNM Stage in Patients with Pancreatic Cancer in the Era of Modern Neoadjuvant Therapy. Co-author DOI 10.1245/s10434-024-16792-7↗
  6. Impact of portal/superior mesenteric vein abutment angle on prognosis in pancreatic cancer: a single-center retrospective cohort study. Co-author DOI 10.4174/astr.2025.108.4.231↗
  7. Predicting prognosis and optimal timing for surgery using CA 19-9 in patients with pancreatic cancer who underwent FOLFIRINOX-based neoadjuvant therapy: a retr… First author DOI 10.4174/astr.2025.109.6.348↗
  8. Role of neoadjuvant treatment in resectable pancreatic cancer according to vessel invasion and increase of CA19-9 levels. Co-author DOI 10.1002/jhbp.1302↗
  9. The incidence and clinical features of familial pancreatic cancer in Korea. Co-author DOI 10.1002/jhbp.1117↗
  10. Can Surgical Resection of Metastatic Lesions Be Beneficial to Pancreatic Ductal Adenocarcinoma Patients with Isolated Lung Metastasis? Co-author DOI 10.3390/cancers14092067↗
  11. Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. First author DOI 10.3390/cancers14184360↗
  12. Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX. Co-author DOI 10.5009/gnl20070↗
  13. Survival outcome and prognostic factors of neoadjuvant treatment followed by resection for borderline resectable pancreatic cancer. Co-author DOI 10.4174/astr.2017.93.4.186↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hongbeom Kim · 11 shared papers, 2017–2026 · strength 2.31
  2. Jin Seok Heo · 7 shared papers, 2025–2026 · strength 1.83
  3. In Woong Han · 7 shared papers, 2025–2026 · strength 1.83
  4. Hochang Chae · 7 shared papers, 2025–2026 · strength 1.83
  5. Sang Hyun Shin · 7 shared papers, 2025–2026 · strength 1.83
  6. So Jeong Yoon · 5 shared papers, 2025 · strength 1.27
  7. Hye Jeong Jeong · 5 shared papers, 2025 · strength 1.23
  8. Jin‐Young Jang · 6 shared papers, 2017–2023 · strength 0.81
  9. Wooil Kwon · 6 shared papers, 2017–2023 · strength 0.81
  10. Mirang Lee · 4 shared papers, 2022–2023 · strength 0.63
  11. Ji Hye Min · 2 shared papers, 2025 · strength 0.47
  12. Jae Seung Kang · 3 shared papers, 2021–2023 · strength 0.43
  13. Won‐Gun Yun · 2 shared papers, 2022 · strength 0.29
  14. Yoonhyeong Byun · 2 shared papers, 2021–2022 · strength 0.25
  15. Song Eun Yoon · 1 shared paper, 2025 · strength 0.25
  16. Seung Hyup Hyun · 1 shared paper, 2025 · strength 0.24
  17. Dong Ho Lee · 1 shared paper, 2023 · strength 0.18
  18. Minseob Kim · 1 shared paper, 2022 · strength 0.16
  19. Michael D. Kluger · 1 shared paper, 2022 · strength 0.15
  20. Alexander S. Thomas · 1 shared paper, 2022 · strength 0.15
  21. Hye‐Sol Jung · 1 shared paper, 2022 · strength 0.14
  22. Woo Hyun Paik · 1 shared paper, 2021 · strength 0.11
  23. Yoo Jin Choi · 1 shared paper, 2021 · strength 0.11
  24. Haeryoung Kim · 1 shared paper, 2021 · strength 0.11
  25. Yong‐Tae Kim · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.